General Updates | Harmonizing sickle cell disease guidelines in the EU

Yes, so we wanted to try to harmonize the national guidelines of different countries in the EU and to see if there are alignments, what kind of guidelines are the same and in what kind of areas there are differences. In this way, we can identify also the gaps. And the main goal was to provide an overview also for countries that do not have any guideline or who have only a very limited guideline to be able to provide them also what is done in Europe, basically. And of course, there are differences. And I think the example is, we have shown this in this poster at ASCAT, that there are small differences when you think about acute chest syndrome, but we looked at different complications, different treatments, also diagnosis, like the whole spectrum of the management of sickle cell disease. And what we did, we compared the national guidelines of the EU countries, those who have a guideline, we looked both at pediatric and adult guidelines and we have tried to harmonize this. This is still a process that is ongoing at this moment. And I think the most important thing is also to find areas where there’s no real consensus yet. And in this way, we can also identify these gaps of knowledge and focus our research on trying to solve these questions.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.